FIELD: medicine.
SUBSTANCE: invention relates to a method for the treatment of a patient with malignant tumor expressing EGFR having a mutation with an insertion in exon 20, with a compound selected from a group consisting of: (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dighydropyrimido[5,4-b]indolysin-8-yl)acrylamide; (S)-N-(4-amino-6-methylene-5-(quinolin-3-yl)-7,8-dighydro-6H-pyrimido[5,4-b]pyrrolizin-7-yl)acrylamide; and (S,E)-N-(4-amino-6-methylene-5-(quinolin-3-yl)-7,8-dihydro-6H-pyrimido[5,4-b]pyrrolizin-7-yl)-3-chloracrylamide; and (R)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dighydropyrimido[5,4-b]indolysin-8-yl)-N-methylacrylamide or its salt. The use of the specified compound for the production of an antitumor agent for the treatment of a patient with malignant tumor expressing EGFR having a mutation with an insertion in exon 20 is also proposed.
EFFECT: obtaining a compound for the treatment of malignant tumor.
9 cl, 15 dwg, 8 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTIVE INHIBITOR OF EGFR HAVING MUTATION IN EXON 18 AND/OR EXON 21 | 2018 |
|
RU2785657C2 |
| L718 AND/OR L792 MUTANT INHIBITOR OF TREATMENT-RESISTANT EGFR | 2019 |
|
RU2809621C2 |
| BISPECIFIC ANTIGEN-BINDING PROTEIN EGFR/CD16 | 2019 |
|
RU2792240C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT USING RECOMBINANT MVA AND ANTIBODIES INTRODUCED INTRAVENOUSLY | 2018 |
|
RU2795103C2 |
| ANTIBODY MOLECULES THAT BIND CD137 AND OX40 | 2019 |
|
RU2817602C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| ANTIBODY AGAINST CD147 | 2018 |
|
RU2785293C2 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
